Spiro Medical is a venture-backed medical device company based in Irvine, California that is building the first purpose-built Pulmonary Neuromodulation System (PNM) for asthma patients. The proprietary implant targets neural reflex pathways in the lungs with the goal of reducing symptoms such as wheezing, shortness of breath, and coughing. Founded by Stephen Pyles, M.D., Kurt Gehlsen, M.D., Ph.D., Rinda Sama, and G. Jay Jiang, Ph.D., the company enters the market with issued patents and initial human data supporting the technology’s clinical potential. Proceeds from its recent financing will fund final system design, clinical trials, and U.S. regulatory work. Leadership claims deep expertise in implantable neuromodulation, positioning the team to build a “world-class” product. Although the company is pre-revenue, it is targeting a large addressable market of more than 28 million U.S. asthma sufferers and 300 million patients worldwide.

Total raised

$67M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2026